
	Where results make sense

Topic: Neurocrine

In the News (Thu 16 Feb 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	BioView.com - Corporate Profile - Neurocrine (Site not responding. Last check: 2007-10-30)
		Neurocrine Biosciences is a leading biopharmaceutical company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders.
		Neurocrine uses an array of medicinal, computational, and combinatorial chemistry techniques to facilitate the analysis of screening data and subsequently search large virtual libraries of novel, readily synthesizable compounds and select for parallel synthesis only those compounds which match the properties of the screening hits.
		Neurocrine scientists have utilized novel techniques for examination of gene expression in a variety of cellular systems and developed unique expression vectors and cell lines that allow for the highly efficient protein expression of specific genes.
	www.bioview.com /job/neurocrine.html (800 words)

	Neurocrine Narrows Loss
		Neurocrine Biosciences (NBIX:Nasdaq - news - research) announced a first-quarter loss that was narrower than a year ago, despite a huge drop in revenue, as the company's core product marches forward in the drug approval process.
		Neurocrine had a first-quarter net loss of $12.4 million, or 35 cents a share, which is a penny better than the 36-cent loss expected by analysts and the loss of $13.4 million, or 43 cents a share, a year ago.
		Neurocrine's research and development expenses plunged in the quarter, coming in at $26.4 million, down 45.3% from the $48.3 million it spent a year ago.
	www.thestreet.com /_tsclsii/stocks/biotech/10157938.html (527 words)

	Neurocrine Biosciences, Inc. (Site not responding. Last check: 2007-10-30)
		Neurocrine is pursing a strategy to maintain a mix of owned and partnered clinical candidates that will optimize shareholder value.
		Neurocrine runs this cycle several times until a defined structure activity relationship is determined and the medicinal chemists have paved a clear path to unique, patentable, drug-like molecules.
		Neurocrine has put in place a preclinical and clinical development infrastructure to advance compounds into early clinical development to document safety and efficacy.
	www.acor.org /drugs/pipeline/companies/Neurocrine+Biosciences,+Inc..tmp (817 words)

	Sleeping on Neurocrine's Shares [Fool.com: Commentary] February 17, 2005
		Neurocrine is going for approval of two forms of Indiplon -- Indiplon-IR, an immediate-release version meant to help get users to sleep initially, and Indiplon-MR, a modified-release version to help users maintain sleep throughout the night.
		(Neurocrine is actually valued slightly higher than ICOS.) The big difference is that ICOS has been hawking Cialis for well over a year, and the company's shares have lost 49% of their value since Cialis was approved.
		But Neurocrine's $1.3 billion enterprise value and its similarities with ICOS suggest to me that there is relatively little upside to the company until we hear more about progress in the pipeline.
	www.fool.com /news/commentary/2005/commentary05021704.htm (1260 words)

	Neurocrine Biosciences Press Releases
		Shares of Neurocrine Biosciences were among the worst-performing health-related stocks Friday, plunging 23% after the drug development company said it might need to conduct more tests on its Indiplon sleeping...
		Neurocrine Biosciences, Inc. announced today that the Company has received communication from the U.S. Food and Drug Administration indicating that the agency has determined that indiplon 5 mg and 10 mg...
		Neurocrine Biosciences, Inc. today announced positive results of its 'proof of concept', safety, efficacy and dose-finding Phase II clinical trial using its proprietary, orally-active small molecule...
	www.topix.net /com/nbix/pr (1492 words)

	Sample Contracts - Collaborative Research and Development Agreement - Neurocrine Biosciences Inc. and Rigel Inc. - ...
		In no instance shall Neurocrine be obligated to screen a Rigel Target that it believes in good faith to be in direct competition with a Neurocrine research and development program existing at the time of the request.
		Neurocrine shall prepare, file, prosecute and maintain patents and/or patent application worldwide, in accordance with Section 6.6, for those inventions within the Neurocrine Technology and within the Joint Technology and any inventions included in the Rigel Technology that are assigned to Neurocrine pursuant to Section 6.5.
		Neurocrine will not be subject to any liability for any settlement of such Claims made by a Rigel Indemnitee without Neurocrine's consent (not to be unreasonably withheld).
	contracts.onecle.com /rigel/neurocrine.rd.1997.12.shtml (3805 words)

	Neurocrine Biosciences Reports First Quarter 2006 Results
		Neurocrine is reconfirming financial guidance for 2006, which excludes the impact associated with indiplon sales and subsequent net royalty revenues but includes the milestones associated with approval.
		Neurocrine is continuing to enroll patients in a second Phase II study in patients with endometriosis that was initiated in December 2005 to more fully explore dose response.
		Neurocrine initiated a Phase I study in the 1st Quarter of 2006 of a new compound, NBI-75043, for the treatment of insomnia.
	www.freshnews.com /news/biotech-biomedical/article_31401.html (2325 words)

	News Search: neurocrine biosciences (Site not responding. Last check: 2007-10-30)
		Neurocrine Biosciences will cut about 100 employees at its San Diego campus under a plan to save about $50 million a year.
		Specifically, Neurocrine Biosciences (NASDAQ: NBIX) declined 83.6% in the quarter versus a 1.4% decline in the S&P 500 and a 7.0% decline in the NASDAQ...
		Neurocrine Biosciences ' decision to lay off its 200-person sales force is a disappointment, according to a report from UBS Investment Research.
	www.topix.net /search?q=neurocrine+biosciences (683 words)

	Indiplon Blog
		Neurocrine will meet with the Food and Drug Administration (FDA) to finalize development plans for the resubmissions of each indiplon NDA and plans to commercialize indiplon as quickly as possible upon approval.
		"Neurocrine Biosciences, Inc. today announced the publication of studies on the mechanism of action of indiplon that confirm its high affinity and selectivity for the subtype of the GABA receptor that is responsible for the principal effect of "non-benzodiazepine" sleep agents.
		Neurocrine also is in Phase II with its Type I diabetes drug, NBI-75043, and its urocortin 2 drug in congestive heart failure.
	www.ambers-website.info /indiplon (3663 words)

	SignOnSanDiego.com > News > Business -- Neurocrine, Pfizer join in $400 million alliance
		Neurocrine Biosciences yesterday landed a deal worth up to $400 million to share rights to an experimental insomnia drug with Pfizer, the world's largest pharmaceutical company.
		A huge, makeshift sign appeared yesterday in front of Neurocrine's Sorrento Valley headquarters – "Indiplon is in bed with Pfizer" – and champagne corks were popping for the company's 250 employees by late afternoon.
		Indiplon is being tested in final, Phase 3 clinical trials, and Neurocrine hopes to apply to the Food and Drug Administration for approval late next year.
	www.signonsandiego.com /news/business/20021220-9999_1b20neuro.html (681 words)

	Sleeping Pills Information Database; Ambien; Rozerem; Lunesta; Sonata
		Neurocrine hopes to have indiplon approved for sleep initiation, sleep maintenance and long term use.
		Neurocrine submitted indiplon to the FDA in April, 2005.
		In December of 2002, Neurocrine finalized an agreement with Pfizer to co-market Indiplon.
	www.coreynahman.com /11_25_sleeping_pills.html (1283 words)

	PharmaDeals - The Global Resource
		Under terms of the collaboration, which is subject to government approval, Neurocrine will receive an initial payment of $100 million and up to $300 million in milestone payments.
		SAN DIEGO, Feb. 25 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the expiration of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act in connection with the global agreement with Pfizer Inc (NYSE: PFE) for the exclusive worldwide development and commercialization of indiplon, Neurocrine's Phase III compound for the treatment of insomnia.
		The expiration of the waiting period triggers the $100 million initial payment to Neurocrine by Pfizer and allows the two companies to actively begin the collaboration for the clinical development and commercialization of indiplon.
	www.pharmaventures.com /ag_demo/prelease_12129.html (1116 words)

	Neurocrine reports successful trial of insomnia drug North County Times - North San Diego and Southwest Riverside ... (Site not responding. Last check: 2007-10-30)
		Neurocrine first reported a successful Phase III trial on Feb. 18, for an immediate-acting form of the drug.
		As the first drug Neurocrine plans to submit for approval (and apparently joining Isis with the second therapeutic drug from a North County-based company), Indiplon is important to Neurocrine's future.
		Pfizer gave $100 million to Neurocrine to help develop the drug and has promised up to $300 million to Neurocrine if the drug is approved, along with 200 sales representatives to help market Indiplon.
	www.nctimes.com /articles/2004/09/10/business/news/20_26_099_9_04.txt (669 words)

	Neurocrine Biosciences Announces Initiation of Phase II Clinical Trial With NBI-5788 for Multiple Sclerosis
		The trial, led by principal investigator Dr. Jack Antel, Professor of Neurology at McGill University in Montreal, is being conducted in approximately 150 male and female patients with MS aged 18 to 55 years in approximately 25 study centers across the United States and Canada.
		Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com.
		The Immune Tolerance Network is an international research consortium that aims to accelerate the clinical development of immune tolerance therapies for use in transplantation, autoimmune diseases and allergy and asthma.
	www.immunetolerance.org /news/articles/itn_news/article_362.html (633 words)

	Neurocrine announces positive GnRH receptor antagonist trials.
		Neurocrine Biosciences has announced positive Phase I clinical trial results with its proprietary, orally active small molecule Gonadotropin-Releasing Hormone (GnRH) receptor antagonist that could diminish bone demineralisation.
		Neurocrine researchers believe this orally active, non-peptide GnRH antagonists should provide the potential to eliminate hormone add-back therapy, a rapid onset of action, an increased dosing flexibility, and a greater patient acceptability over currently available treatments.
		The trial was designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of two dose levels of NBI-56418 given once daily for 6 weeks in 60 healthy pre- menopausal women.
	drugresearcher.com /news/news-NG.asp?n=58466-neurocrine-announces-gnrh (764 words)

	Neurocrine Ends MS Drug Effort
		Neurocrine says the FDA is expected to act in mid-May.
		Neurocrine said Wednesday the drug will likely be classified as a Schedule IV drug, the second-mildest DEA designation.
		The trial was discontinued due to "systemic hypersensitivity-type reactions." Neurocrine reacquired the rights to the compound in January 2000 and commenced a new trial in 2003.
	www.thestreet.com /_tscrss/stocks/pharmaceuticals/10272556.html (370 words)

	NewsRx Search Results on NBIX (Site not responding. Last check: 2007-10-30)
		Neurocrine Biosciences, Inc. (NBIX) announced that for the first quarter of 2006, the company reported a net loss of $25.9...
		Neurocrine Biosciences, Inc. (NBIX) announced the appointment of Chris O'Brien, MD to the position of senior vice president...
		Neurocrine Biosciences, Inc., (NBIX) announced the appointment of Richard Ranieri to the position of senior vice...
	www.newsrx.com /search_results.php?search_term=NBIX (512 words)

	News On Narcolepsy
		In humans with narcolepsy there appears to be a loss of hypocretin, a neuropeptide important in the control of sleep.
		Neurocrine scientists will use high throughput screens to identify small molecule hypocretin-2 receptor agonists with good potency and efficacy.
		Narcolepsy is a disabling sleep disorder characterized by excessive daytime sleepiness and abnormal manifestations of Rapid Eye Movement (REM) sleep, including cataplexy, which is a sudden loss of strength in voluntary muscles, sleep paralysis and hypnagogic hallucinations.
	www.cataplexic.com /news.html (2531 words)

	Neurocrine Biosciences Reports Third Quarter 2005 Results
		Neurocrine recently completed a randomized, double-blind, active- and placebo-controlled, four-way crossover, out-patient clinical trial conducted in 30 healthy volunteers to measure the impairment on next day driving performance after nighttime administration of indiplon 10mg, and 15mg, zopiclone 7.5mg or placebo.
		Neurocrine has completed enrollment in a Phase II, dose-response, efficacy and safety trial in approximately 190 adults/adolescents with new onset Type 1 Diabetes.
		Neurocrine will file an IND in the fourth quarter of 2005 for the evaluation of safety and efficacy of a new compound, NBI-75043, for the treatment of insomnia.
	www.freshnews.com /news/biotech-biomedical/article_27694.html (1904 words)

	Neurocrine takes delivery of Genedata’s Computational High Throughput Gene Expression Analysis System
		Scientists at Neurocrine will use Expressionist in its pre-clinical discovery program, which focuses on neurological and endocrine-related diseases and disorders.
		“We are pleased to support Neurocrine in their research efforts”, says Matthew Trunnell, Managing Director USA, Genedata Inc. Large-scale analysis of gene expression data poses significant technical challenges.
		About Neurocrine Biosciences Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders.
	www.genedata.com /press/pressreleases/2005/neurocrine/index_eng.html (406 words)

	BigCharts - QuickCharts
		Neurocrine Biosciences to cut 100 jobs in San Diego
		Neurocrine Biosciences Reports Second Quarter 2006 Results - PR Newswire
		Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2006 Financial Results - PR Newswire
	bigcharts.marketwatch.com /quickchart/quickchart.asp?symb=nbix (328 words)

	Pfizer forges insomnia drug deal with Neurocrine - Dec. 19, 2002 (Site not responding. Last check: 2007-10-30)
		San Diego, Calif.-based Neurocrine would receive an upfront payment of $100 million and up to $300 million in milestone payments under the deal, which must be approved by regulators, the companies said in a release.
		Pfizer (PFE: Research, Estimates) said it will have exclusive rights to develop and sell the drug, called indiplon, outside the United States, in exchange for paying Neurocrine royalties.
		After the launch of the insomnia drug in the United States, Pfizer said it would grant Neurocrine loans of up to $175 million.
	money.cnn.com /2002/12/19/news/companies/pfizer.reut (292 words)

	Healthcare Sales & Marketing Network News: Neurocrine Biosciences Announces Appointment of Senior Vice President of ...
		SAN DIEGO, Oct. 31 (HSMN NewsFeed) -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Chris O'Brien, M.D. to the position of Senior Vice President of Clinical Development.
		In this position, Dr. O'Brien will be responsible for leading Neurocrine's Clinical Development efforts with five compounds currently in clinical trials and three new compounds expected to enter the clinic within the next year.
		The options were granted outside of the Company's stockholder approved option plan in accordance with NASDAQ rules and will vest over a four-year period.
	www.salesandmarketingnetwork.com /news_release.php?ID=2008146 (389 words)

	Neurocrine Biosciences Stock Report (NBIX) \| Quote & News
		Neurocrine Biosciences Reports Second Quarter 2006 Results (PRN)
		Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2006 Financial Results (PRN)
		Neurocrine Biosciences is a research-based pharmaceutical company advancing drug candidates in the CNS and endocrine-related categories.
	quote.morningstar.com /quote.html?ticker=nbix&pmts=sq3 (247 words)

	Neurocrine Biosciences, Inc.
		16:59 ET Neurocrine Biosciences Announces Resubmission Status of Indiplon
		08:01 ET Neurocrine Biosciences Announces Six Abstracts on Indiplon to Be Presented at the Associated Professional Sleep Societies (APSS) Meeting, June 3-8
		08:05 ET Neurocrine Biosciences to Present at the UBS Warburg Global Specialty Pharmaceuticals Conference on Wednesday, June 4, 2003
	www.prnewswire.com /gh/cnoc/comp/604138.html (2123 words)

	Neurocrine Biosciences - Analyst News \| newratings.com (Site not responding. Last check: 2007-10-30)
		Quote data by IS.eFinance Solutions using Standard&Poor's ComStock Inc. and others.
		Neurocrine shares plummet as FDA rejects sleeping pill
		Neurocrine Biosciences "neutral," target price reduced - update
	www.newratings.com /analyst_news/company_US64125C1099.html (146 words)

Try your search on: Qwika (all wikis)